Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 29

1.

Risedronate directly inhibits osteoclast differentiation and inflammatory bone loss.

Kwak HB, Kim JY, Kim KJ, Choi MK, Kim JJ, Kim KM, Shin YI, Lee MS, Kim HS, Kim JW, Chun CH, Cho HJ, Hong GY, Juhng SK, Yoon KH, Park BH, Bae JM, Han JK, Oh J.

Biol Pharm Bull. 2009 Jul;32(7):1193-8.

2.

Decreased bone mineral density with off-label use of tenofovir in children and adolescents infected with human immunodeficiency virus.

Purdy JB, Gafni RI, Reynolds JC, Zeichner S, Hazra R.

J Pediatr. 2008 Apr;152(4):582-4. doi: 10.1016/j.jpeds.2007.12.020.

3.

Nucleoside reverse transcriptase inhibitors (NRTIs)-induced expression profile of mitochondria-related genes in the mouse liver.

Desai VG, Lee T, Delongchamp RR, Leakey JE, Lewis SM, Lee F, Moland CL, Branham WS, Fuscoe JC.

Mitochondrion. 2008 Mar;8(2):181-95. doi: 10.1016/j.mito.2008.01.002. Epub 2008 Feb 1.

PMID:
18313992
4.
5.

Skeletal abnormalities and extra-skeletal ossification in mice with restricted Gsalpha deletion caused by a renin promoter-Cre transgene.

Castrop H, Oppermann M, Mizel D, Huang Y, Faulhaber-Walter R, Weiss Y, Weinstein LS, Chen M, Germain S, Lu H, Ragland D, Schimel DM, Schnermann J.

Cell Tissue Res. 2007 Dec;330(3):487-501. Epub 2007 Oct 6.

PMID:
17922144
6.

Non-coding RNAs: lessons from the small nuclear and small nucleolar RNAs.

Matera AG, Terns RM, Terns MP.

Nat Rev Mol Cell Biol. 2007 Mar;8(3):209-20. doi: 10.1038/nrm2124. Review.

PMID:
17318225
7.

Comparative effects of five bisphosphonates on apoptosis of macrophage cells in vitro.

Moreau MF, Guillet C, Massin P, Chevalier S, Gascan H, Baslé MF, Chappard D.

Biochem Pharmacol. 2007 Mar 1;73(5):718-23. Epub 2006 Nov 3.

PMID:
17157266
8.

Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: impact on bone mineral density in HIV-infected children.

Gafni RI, Hazra R, Reynolds JC, Maldarelli F, Tullio AN, DeCarlo E, Worrell CJ, Flaherty JF, Yale K, Kearney BP, Zeichner SL.

Pediatrics. 2006 Sep;118(3):e711-8. Epub 2006 Aug 21.

PMID:
16923923
9.

Lack of pharmacokinetic drug interaction between tenofovir disoproxil fumarate and nelfinavir mesylate.

Boffito M, Pozniak A, Kearney BP, Higgs C, Mathias A, Zhong L, Shah J.

Antimicrob Agents Chemother. 2005 Oct;49(10):4386-9.

10.

Deficiency of the G-protein alpha-subunit G(s)alpha in osteoblasts leads to differential effects on trabecular and cortical bone.

Sakamoto A, Chen M, Nakamura T, Xie T, Karsenty G, Weinstein LS.

J Biol Chem. 2005 Jun 3;280(22):21369-75. Epub 2005 Mar 28.

11.

Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial.

Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, Miller MD, Coakley DF, Lu B, Toole JJ, Cheng AK; 903 Study Group.

JAMA. 2004 Jul 14;292(2):191-201.

PMID:
15249568
12.

Biological effects of short-term or prolonged administration of 9-[2-(phosphonomethoxy)propyl]adenine (tenofovir) to newborn and infant rhesus macaques.

Van Rompay KK, Brignolo LL, Meyer DJ, Jerome C, Tarara R, Spinner A, Hamilton M, Hirst LL, Bennett DR, Canfield DR, Dearman TG, Von Morgenland W, Allen PC, Valverde C, Castillo AB, Martin RB, Samii VF, Bendele R, Desjardins J, Marthas ML, Pedersen NC, Bischofberger N.

Antimicrob Agents Chemother. 2004 May;48(5):1469-87. Erratum in: Antimicrob Agents Chemother. 2994 Jan;48(6):2346.

13.

Antiretroviral nucleoside and nucleotide analogues and mitochondria.

Cossarizza A, Moyle G.

AIDS. 2004 Jan 23;18(2):137-51. Review. No abstract available.

PMID:
15075530
14.

Metabolic changes in the knockout mouse for Canavan's disease: implications for patients with Canavan's disease.

Surendran S, Matalon KM, Szucs S, Tyring SK, Matalon R.

J Child Neurol. 2003 Sep;18(9):611-5.

PMID:
14572139
15.

Exploration, normalization, and summaries of high density oligonucleotide array probe level data.

Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, Speed TP.

Biostatistics. 2003 Apr;4(2):249-64.

16.

Tenofovir treatment at 30 mg/kg/day can inhibit cortical bone mineralization in growing rhesus monkeys (Macaca mulatta).

Castillo AB, Tarantal AF, Watnik MR, Martin RB.

J Orthop Res. 2002 Nov;20(6):1185-9.

17.

Tenofovir exhibits low cytotoxicity in various human cell types: comparison with other nucleoside reverse transcriptase inhibitors.

Cihlar T, Birkus G, Greenwalt DE, Hitchcock MJ.

Antiviral Res. 2002 Apr;54(1):37-45.

PMID:
11888656
18.

Periodontal diseases and osteoporosis: association and mechanisms.

Wactawski-Wende J.

Ann Periodontol. 2001 Dec;6(1):197-208. Review.

PMID:
11887465
19.
20.

The microphthalmia transcription factor and the related helix-loop-helix zipper factors TFE-3 and TFE-C collaborate to activate the tartrate-resistant acid phosphatase promoter.

Mansky KC, Sulzbacher S, Purdom G, Nelsen L, Hume DA, Rehli M, Ostrowski MC.

J Leukoc Biol. 2002 Feb;71(2):304-10.

PMID:
11818452

Supplemental Content

Support Center